Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.90
-2.0%
$12.40
$10.45
$21.69
$4.92B0.62721,030 shs294,386 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$97.76
-1.3%
$98.28
$77.10
$163.71
$5.58B0.82748,406 shs599,069 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$87.20
-0.5%
$79.81
$41.50
$90.32
$4.39B-2.63856,334 shs1.19 million shs
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$7.93
-4.7%
$6.34
$0.32
$22.42
$1.54BN/A522,650 shs197,962 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+0.14%+20.74%+15.19%-17.11%
Glaukos Corporation stock logo
GKOS
Glaukos
0.00%-5.71%-4.45%+8.44%-21.25%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%+6.90%+9.85%+24.61%+79.13%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
0.00%+58.92%+62.50%+792,999,900.00%+792,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
3.0875 of 5 stars
3.12.00.00.02.01.72.5
Glaukos Corporation stock logo
GKOS
Glaukos
4.4569 of 5 stars
4.41.00.04.43.31.70.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.2861 of 5 stars
3.51.00.04.63.42.50.6
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.17
Hold$15.4511.18% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6737.75% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.09
Buy$108.7024.66% Upside
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SSII, GKOS, BLCO, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Glaukos Corporation stock logo
GKOS
Glaukos
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/11/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$105.00 ➝ $121.00
7/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$13.00 ➝ $15.00
7/8/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.50 ➝ $16.00
6/23/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
6/23/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$110.00
6/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $97.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.00
5/6/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/6/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.03$1.87 per share7.42$18.57 per share0.75
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M14.57N/AN/A$13.91 per share7.03
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$22.13M69.37N/AN/A$0.08 per share99.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A14.481.57-7.50%2.62%1.28%7/30/2025 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
-$19.15MN/A0.00N/A-67.73%-70.64%-32.95%N/A

Latest SSII, GKOS, BLCO, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.85N/AN/AN/A$3.91 millionN/A
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.07N/AN/AN/A$1.25 billionN/A
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26N/AN/AN/A$115.49 millionN/A
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.14-$0.95+$0.19-$0.95N/AN/A
4/30/2025Q1 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.74
1.56
0.96
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
6.49
5.62
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
19.64
19.64
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A
3.18
2.22

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.80 million351.12 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.14 million53.83 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3050.39 million47.17 millionOptionable
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
4193.60 millionN/AN/A

Recent News About These Companies

SSII - SS Innovations International Inc Ownership | Morningstar
SS Innovations: A Speculative Bet On Robotic Surgeries

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.90 -0.28 (-1.97%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$13.91 +0.01 (+0.07%)
As of 07/18/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$97.76 -1.24 (-1.25%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$97.72 -0.04 (-0.04%)
As of 07/18/2025 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$87.20 -0.44 (-0.50%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$87.16 -0.05 (-0.05%)
As of 07/18/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SS Innovations International stock logo

SS Innovations International NASDAQ:SSII

$7.93 -0.39 (-4.69%)
As of 07/18/2025 04:00 PM Eastern

AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.